Navigation

nicotine inhaled (Nicorette Inhaler, Nicotrol Inhaler)

 

Classes: Smoking Cessation Aids

Dosing and uses of Nicorette Inhaler, Nicotrol Inhaler (nicotine inhaled)

 

Adult dosage forms and strengths

oral inhaler

  • 10mg/cartridge (4 mg delivered)

 

Smoking Cessation

Indicated to reduce withdrawal symptoms during smoking cessation

Best effect observed with frequent, continuous puffing over 20 minute periods throughout the day

6 or more cartridges/day PRN [4 mg/cartridge]; do not exceed 16 cartridges/day

Use at least 6 cartridges/day for the first 3-6 weeks for improved success at quiting

 

Administration

Before initiating nicotine replacement reatment, patient must have desire to stop smoking

Most effective as part of comprehensive smoking cessation plan

See product user's guides for details

 

Pediatric dosage forms and strengths

Not recommended

 

Nicorette Inhaler, Nicotrol Inhaler (nicotine inhaled) adverse (side) effects

>10%

Mouth/throat irritation (66%)

Cough (32%)

Headache (18-26%)

Rhinitis (23%)

Dyspepsia (18%)

 

1-10%

Back pain (6%)

Arthralgia (5%)

Flatulence (4%)

Gum problems (4%)

Acne (3%)

Dysmenorrhea (3%)

 

<1%

Nicotine withdrawal (irritability, dizziness, headache, insomnia)

Hiccups

N/V

Anorexia

Diarrhea

Increased salivation

Cardiac dysrhythmia (rare)

Hypertension (rare)

Tachyarrhythmia (rare)

Immune hypersensitivity reaction (rare)

 

Warnings

Contraindications

Hypersensitivity to nicotine or components

Active smokers following the postmyocardial period

Patients with life-threatening arrhythmias or worsening of angina pectoris if severe

Nonsmokers

 

Cautions

Not studied in reactive airway disease; may cause bronchospasm

Caution with hypertension, cardiovascular, or peripheral vascular disease

Caution with hyperthyroidism, pheochromocytoma, or insulin-dependent diabetes, since nicotine causes the release of catecholamines by the adrenal medulla

Delays healing of peptic ulcer disease

Use caution in patients with oropharyngeal inflammation, peptic ulcer, or history of esophagitis

Caution in severe renal impairment

 

Pregnancy and lactation

Pregnancy category: d

Lactation: Unknown whether excreted in breast milk; use caution

 

Pregnancy categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

 

Pharmacology of Nicorette Inhaler, Nicotrol Inhaler (nicotine inhaled)

Mechanism of action

Agonist at nicotinic receptors; potent ganglionic and central nervous stimulant

 

Absorption

Peak plasma time: 15 minutes

 

Distribution

Protein binding: <5%

Vd: 2-3 L/kg

 

Metabolism

Metabolism: liver (some renal, lung)

Metabolites: over 20, less active

 

Elimination

Clearance: 1.2 L/min

Excretion: urine (30%)